| Autor: |
Undvall Anand E; Department of Biomedical Engineering, Lund University, 221 00 Lund, Sweden., Magnusson C; Department of Translational Medicine, Lund University, 205 02 Malmö, Sweden., Lenshof A; Department of Biomedical Engineering, Lund University, 221 00 Lund, Sweden., Ceder Y; Department of Laboratory Medicine, Lund University, 221 00 Lund, Sweden., Lilja H; Department of Translational Medicine, Lund University, 205 02 Malmö, Sweden.; Department of Laboratory Medicine, Surgery (Urology), and Medicine (GU Oncology), Memorial Sloan-Kettering Cancer Center, New York, New York 10065, United States., Laurell T; Department of Biomedical Engineering, Lund University, 221 00 Lund, Sweden. |
| Abstrakt: |
There is an unmet clinical need to extract living circulating tumor cells (CTCs) for functional studies and in vitro expansion to enable drug testing and predict responses to therapy in metastatic cancer. Here, we present a novel two-step acoustophoresis (A 2 ) method for isolation of unfixed, viable cancer cells from red blood cell (RBC) lysed whole blood. The A 2 method uses an initial acoustofluidic preseparation step to separate cells based on their acoustic mobility. This acoustofluidic step enriches viable cancer cells in a central outlet, but a significant number of white blood cells (WBCs) remain in the central outlet fraction due to overlapping acoustophysical properties of these viable cells. A subsequent purging step was employed to remove contaminating WBCs through negative selection acoustophoresis with anti-CD45-functionalized negative acoustic contrast particles. We processed 1 mL samples of 1:1 diluted RBC lysed whole blood mixed with 10 000 DU145 cells through the A 2 method. Additional experiments were performed using 1000 DU145 cells spiked into 1.5 × 10 6 WBCs in 1 mL of buffer to further elucidate the dynamic range of the method. Using samples with 10 000 DU145 cells, we obtained 459 ± 188-fold depletion of WBC and 42% recovery of viable cancer cells. Based on spiked samples with 1000 DU145 cells, our cancer cell recovery was 28% with 247 ± 156-fold WBC depletion corresponding to a depletion efficacy of ≥99.5%. The novel A 2 method provides extensive elimination of WBCs combined with the gentle recovery of viable cancer cells suitable for downstream functional analyses and in vitro culture. |
